Payment overview · 2025
General Payments
$879.39
40 reported records · 9 companies
Healthcare provider profile · identity verified
Abdulmalek Sabbagh, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · WESTON, WV · NPI 1427018837
Verified facts
What the public records show
CMS Open Payments records show Abdulmalek Sabbagh, MD received $879.39 in general payments during 2025 across 40 reported records.
CSL Behring accounted for 32.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brilinta, Eliquis, Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 404 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| CSL Behring | Unresolved — no canonical attribution shown | $286.68 | 32.6% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $124.04 | 14.1% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $101.12 | 11.5% | 6 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $86.84 | 9.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.69 | 8.8% | 4 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $71.74 | 8.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $67.50 | 7.7% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $37.62 | 4.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $26.16 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $879.39 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Andembry Normalized: andembry |
Biological | CSL Behring | $206.60 | 7 | 2025 |
Source payment records
|
|||||
| Haegarda Normalized: haegarda |
Biological | CSL Behring | $148.48 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $101.12 | 6 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $86.84 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $77.69 | 4 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $71.74 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $51.27 | 3 | 2025 |
Source payment records
|
|||||
| General - Balloon Catheters Normalized: general balloon catheters |
Device | Boston Scientific Corporation | $41.51 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $37.62 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $33.29 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $26.16 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $25.99 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| BRILINTA Normalized: brilinta |
Drug | AstraZeneca Pharmaceuticals LP | $19.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRILINTA brilinta |
2025 | Brilinta | 2024 | 76 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 404 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
76 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
200 | 43 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
404 | 116 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Tartrate | Metoprolol Tartrate | 819 | 262 |
| Atorvastatin Calcium | Atorvastatin Calcium | 800 | 255 |
| Clopidogrel | Clopidogrel Bisulfate | 787 | 248 |
| Metoprolol Succinate | Metoprolol Succinate | 613 | 213 |
| Furosemide | Furosemide | 462 | 163 |
| Lisinopril | Lisinopril | 459 | 162 |
| Eliquis | Apixaban | 404 | 116 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 370 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 362 | 118 |
| Pantoprazole Sodium | Pantoprazole Sodium | 273 | 85 |
| Losartan Potassium | Losartan Potassium | 261 | 87 |
| Xarelto | Rivaroxaban | 236 | 59 |
| Entresto | Sacubitril/Valsartan | 200 | 43 |
| Atenolol | Atenolol | 199 | 63 |
| Amiodarone Hcl | Amiodarone Hcl | 195 | 71 |
| Digoxin | Digoxin | 184 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 183 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 165 | 52 |
| Warfarin Sodium | Warfarin Sodium | 157 | 45 |
| Nitroglycerin | Nitroglycerin | 149 | 101 |
| Omeprazole | Omeprazole | 119 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 29 |
| Carvedilol | Carvedilol | 93 | 36 |
| Metformin Hcl | Metformin Hcl | 93 | 35 |
| Spironolactone | Spironolactone | 87 | 36 |
| Simvastatin | Simvastatin | 80 | 23 |
| Levothyroxine Sodium | Levothyroxine Sodium | 77 | 30 |
| Brilinta | Ticagrelor | 76 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 76 | 23 |
| Ranolazine Er | Ranolazine | 72 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 68 | 23 |
| Potassium Chloride | Potassium Chloride | 60 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 59 | 18 |
| Ramipril | Ramipril | 59 | 20 |
| Valsartan | Valsartan | 57 | 17 |
| Allopurinol | Allopurinol | 54 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 12 |
| Sotalol | Sotalol Hcl | 39 | 14 |
| Flecainide Acetate | Flecainide Acetate | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | 11 |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Famotidine | Famotidine | 29 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Multaq | Dronedarone Hcl | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 12 |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 21 | 11 |
| Verapamil Sr | Verapamil Hcl | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 14 |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Cartia Xt | Diltiazem Hcl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $879.39 · 40 records | CSL Behring | AIRSUPRA, AVVIGO Guidance System, Andembry, Assure WCD, BREZTRI, BRILINTA, ELIQUIS, FARXIGA, General - Balloon Catheters, Haegarda, LEQVIO, VERQUVO, Wegovy, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brilinta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error